Rishi Sharma, MD
Infectious Disease · Beachwood, OHNPI 1225472376
Payments from drug & device makers
Across 19 payments — averaging $20.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$214
- Tetraphase Pharmaceuticals, Inc.$103
- Insmed, Inc.$32
- Novo Nordisk$17
- Merck$16
What the payments were for
- Food & beverage$34991%
- Education$329%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 14 | $214 |
| Tetraphase Pharmaceuticals, Inc. | 1 | $103 |
| Insmed, Inc. | 2 | $32 |
| Novo Nordisk | 1 | $17 |
| Merck | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Xerava$103
How this compares
$382 in reported general payments places this provider in the 50th percentile of 308 infectious disease providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErtapenemErtapenem Sodium | 40 | $11,038 |
| CeftriaxoneCeftriaxone Sodium | 97 | $10,964 |
| Vancomycin Hcl | 49 | $8,925 |
| Cefepime Hcl | 23 | $6,844 |
| Piperacillin-TazobactamPiperacillin Sodium/Tazobactam | 27 | $5,881 |
| Ampicillin Sodium | 18 | $4,121 |
| Nafcillin Sodium | 12 | $3,679 |
| Cefazolin Sodium | 52 | $3,167 |
| Sodium Chloride0.9 % Sodium Chloride | 55 | $974 |
| Doxycycline Monohydrate | 18 | $478 |
| Cephalexin | 40 | $397 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 23 | $245 |
| Amoxicillin | 24 | $172 |
| Ciprofloxacin Hcl | 17 | $150 |
| Cefdinir | 11 | $132 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Beachwood
- Robert SalataCleveland$2.8M
- Carl FichtenbaumCincinnati$1.6M
- Curtis DonskeyCleveland$1.6M
- Moises Huaman JooCincinnati$1.2M
- Robin JumpCleveland$1.2M
- Grace McComseyCleveland$1M
- Robert BonomoCleveland$1M
- Ian BairdColumbus$810K
- Thomas HerchlineDayton$789K
- John CafardiCincinnati$719K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.